As HIV prevention evolves, long-acting injectable options like lenacapavir are emerging as promising tools to expand access and adherence. Effective implementation of new interventions calls for thoughtful planning across key areas, including operations, staffing, finance, and patient access.
In the first webinar of the series, faculty – including principal investigators from the PURPOSE trials – review clinical data and delve into opportunities and challenges for the real-world implementation of lenacapavir as PrEP.
This webinar covers medication administration, managing side effects, potential drug interactions, and transitioning patients on or off lenacapavir as PrEP.